Queerty is better as a member
This isn’t news … The news from the conference is Sangamo’s “Functional Cure” for HIV/AIDS which is getting virtually no coverage.
Tiny Sangamo BioSciences Inc.’s potential “functional cure” for HIV is getting big attention in advance of a major AIDS scientific meeting.
SB-728-T, a gene therapy designed to knock out the CCR5 receptor on CD4 cells, protects and increases CD4s in patients experiencing poor immunologic recovery while on antiretroviral (ARV) therapy, according to preliminary Phase I study data reported on Monday, February 28, at the 18th Conference on Retroviruses and Opportunistic Infections (CROI) in Boston. The new results, reported by Jay Lalezari, MD, are among the first from a human study illustrating the therapeutic—and curative—potential of this novel approach being developed by Sangamo BioSciences.
Need an account? Register It's free and easy.
PHOTOS: Costumed Hunks Get Into La Leche Halloween in New York City
Meet The Adorable Boyfriend Duo That Dresses CFDA Icon Of The Year Rihanna
PHOTOS: Vintage Fashion Ads From The 1980s
PHOTOS: Uptown, Downtown and Upside Down at the New York Boylesque Festival
PHOTOS: Gay Cowboys Lasso The American West